| Name | Ochromycinone |
| Description | Ochromycinone (STA 21) is a selective STAT3 inhibitor. |
| Cell Research | Human breast cancer cell lines MDA-MB-231, MDA-MB-435s, MDA-MB-453, MDA-MB-468, and MCF7, human ovarian carcinoma cell line Caov-3, and human skin fibroblasts were cultured in DMEM containing 10% FBS and appropriate antibiotics in a 5% CO2 incubator at 37°C. For testing different compounds, the cells were exposed to the compounds for 48 h at a final concentration of 20 or 30 μM, respectively. Then, the cells were harvested and subjected to flow-cytometry analysis.(Only for Reference) |
| In vitro | In cells, Ochromycinone inhibits Stat3 DNA binding activity, Stat3 dimerization, and Stat3-dependent luciferase activity. Ochromycinone remarkably inhibits the growth and the survival of the breast carcinoma cells MDA-MB-231, MDA-MB-435s, and MDA-MB-468 that express persistently activated Stat3. [1] In RH30 and RD2 cells, Ochromycinone also inhibits cell viability and growth and induced apoptosis through caspases 3, 8 and 9 pathways. [2] |
| In vivo | In IL-1Ra–KO mice, STA-21 (0.5 mg/kg, i.p.) reduces the arthritis score and the incidence of arthritis by decreasing the proportion of Th17 cells and increasing the proportion of Treg cells expressing FoxP3. [3] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn Oil : 1.5 mg/mL (4.9 mM), Sonication is recommended.
Ethanol : 2 mg/mL (6.53 mM), Sonication is recommended.
DMSO : 20 mg/mL (65.29 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | STAT3 | STAT | Ochromycinone | Inhibitor | inhibit | DNA | dimerization | binding | Bacterial | antimicrobial | anticancer | antibiotic |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Bioactive Compound Library | Antibiotics Library | Drug Repurposing Compound Library | Microbial Natural Product Library | Inhibitor Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
